Summary of Key Points Core Viewpoint - Hangzhou Minsheng Health Pharmaceutical Co., Ltd. has initiated a share repurchase plan to enhance shareholder value and implement equity incentives, with progress reported as of August 31, 2025 [1][2]. Group 1: Repurchase Plan Overview - The repurchase plan was approved on March 19, 2025, with a maximum repurchase price set at 19.80 CNY per share, targeting the acquisition of 1.3 million to 1.45 million shares, with a total funding limit of 28.71 million CNY [2]. - The implementation period for the repurchase is 12 months from the date of board approval [2]. Group 2: Progress Details - As of August 31, 2025, the company has repurchased a total of 1.328 million shares, representing 0.37% of the current total share capital [3]. - The highest transaction price during the repurchase was 13.82 CNY per share, while the lowest was 11.83 CNY per share, with a total expenditure of approximately 17.26 million CNY (excluding transaction fees) [3]. Group 3: Compliance and Future Plans - The share repurchase activities have complied with relevant regulations, avoiding sensitive periods that could affect stock prices [4]. - The company plans to continue the repurchase based on market conditions within the designated timeframe and will fulfill information disclosure obligations as required [4].
杭州民生健康药业回购进展：已回购132.8万股，支付1726.28万元